journal
https://read.qxmd.com/read/38324103/safety-and-effectiveness-of-antidysrhythmic-drugs-for-pharmacologic-cardioversion-of-recent-onset-atrial-fibrillation-a-systematic-review-and-bayesian-network-meta-analysis
#21
REVIEW
Ian S deSouza, Pragati Shrestha, Robert Allen, Jessica Koos, Henry Thode
PURPOSE: The available evidence to determine which antidysrhythmic drug is superior for pharmacologic cardioversion of recent-onset (onset within 48 h) atrial fibrillation (AF) is uncertain. We aimed to identify the safest and most effective agent for pharmacologic cardioversion of recent-onset AF in the emergency department. METHODS: We searched MEDLINE, Embase, and Web of Science from inception to February 21, 2023 (PROSPERO: CRD42018083781). Eligible studies were randomized controlled trials that enrolled adult participants with AF ≤ 48 h, compared a guideline-recommended antidysrhythmic drug with another antidysrhythmic drug or a different formulation of the same drug or placebo and reported specific adverse events...
February 7, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38319470/acute-kidney-injury-in-different-anticoagulation-strategies-a-large-scale-pharmacoepidemiologic-study-using-real-world-data
#22
JOURNAL ARTICLE
Qiuyu Xu, Gang Chen, Sanxi Ai, Ke Zheng, Bin Zhao, Xuemei Li
PURPOSE: Acute kidney injury (AKI) following anticoagulant application has received growing attention as a significant emerging complication of anticoagulation. Nevertheless, there remains a lack of real-world studies to compare the incidence, clinical features, and prognosis of AKI across different anticoagulant regimens. METHODS: Disproportionality analysis and Bayesian analysis were used to identify suspected AKI cases after different anticoagulant use within the Food and Drug Administration's Adverse Event Reporting System from January 2004 to March 2023...
February 6, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38319468/the-case-continues-to-build-more-data-that-intracoronary-thrombolysis-is-safe-and-effective-in-stemi
#23
EDITORIAL
Spencer Ng, Kevin Friede, George A Stouffer
No abstract text is available yet for this article.
February 6, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38319469/dapagliflozin-for-atrial-fibrillation
#24
EDITORIAL
Na Li, Mihail G Chelu, Yochai Birnbaum
No abstract text is available yet for this article.
February 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38294596/il-33-in-atherosclerosis-an-insufficiently-explored-and-controversial-research-area
#25
LETTER
Yanyan Ye, Fangyuan Chang, Yingchun Xu
No abstract text is available yet for this article.
January 31, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38289454/changes-in-heart-rate-variability-parameters-following-radiofrequency-ablation-in-patients-with-atrial-fibrillation-a-systematic-review-and-meta-analysis
#26
REVIEW
Mahsa Mansourian, Zahra Teimouri-Jervekani, Azam Soleimani, Rasool Nouri, Hamidreza Marateb, Marjan Mansourian
PURPOSE: Radiofrequency (RF) ablation is a prevalent treatment for atrial fibrillation (AF), targeting triggers within the pulmonary vein (PV) for elimination. This study evaluated heart rate variability (HRV) parameter changes at three intervals post-RF ablation: short-term (immediately to 1 month), medium-term (1 to 6 months), and long-term (6 months to 1 year). We compared two ablation techniques: circumferential PV isolation (CPVI) and segmental PV isolation (SPVI). METHODS: A thorough search of databases, including PubMed, Embase, Scopus, Web of Science, and Cochrane, in 2022 yielded 835 pertinent studies...
January 30, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38289453/hyperkalaemia-in-cardiological-patients-new-solutions-for-an-old-problem
#27
REVIEW
Maurizio Giuseppe Abrignani, Edoardo Gronda, Marco Marini, Mauro Gori, Massimo Iacoviello, Pier Luigi Temporelli, Manuela Benvenuto, Giulio Binaghi, Arturo Cesaro, Alessandro Maloberti, Maria Denitza Tinti, Carmine Riccio, Furio Colivicchi, Massimo Grimaldi, Domenico Gabrielli, Fabrizio Oliva
Hyperkalaemia is one of the most common electrolyte disorders in patients with cardiovascular disease (CVD). The true burden of hyperkalaemia in the real-world setting can be difficult to assess, but in population-based cohort studies up to 4 in 10 patients developed hyperkalaemia. In addition to drugs interfering with potassium metabolism and food intake, several conditions can cause or worsen hyperkalaemia, such as advanced age, diabetes, and chronic kidney disease. Mortality, cardiovascular morbidity, and hospitalisation are higher in patients with hyperkalaemia...
January 30, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38289452/the-function-of-circular-rnas-in-myocardial-ischemia-reperfusion-injury-underlying-mechanisms-and-therapeutic-advancement
#28
REVIEW
Kai-Yuan Chen, Zhou Liu, Jun-Hou Lu, Si-Yuan Yang, Xuan-Yi Hu, Gui-You Liang
Myocardial ischemia reperfusion injury (MIRI) represents a prevalent and severe cardiovascular condition that arises primarily after myocardial infarction recanalization, cardiopulmonary bypass surgery, and both stable and unstable angina pectoris. MIRI can induce malignant arrhythmias and heart failure, thereby increasing the morbidity and mortality rates associated with cardiovascular diseases. Hence, it is important to assess the potential pathological mechanisms of MIRI and develop effective treatments...
January 30, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38277064/open-issues-in-the-management-of-otcagerian-patients-with-atrial-fibrillation-and-chronic-kidney-disease-are-we-ready-for-left-atrial-appendage-occlusion-laao-as-first-line-therapy-for-thromboembolic-risk-prevention
#29
EDITORIAL
Francesco Condello, Angelica Cersosimo, Riccardo Cappato, Paolo Pagnotta
No abstract text is available yet for this article.
January 26, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38270692/instent-cto-what-is-the-best-treatment-strategy
#30
EDITORIAL
Mark Sahyouni, George A Stouffer
No abstract text is available yet for this article.
January 25, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38270691/the-toll-like-receptor-2-4-antagonist-sparstolonin-b-and-inflammatory-diseases-a-literature-mining-and-network-analysis
#31
JOURNAL ARTICLE
Rongyuan Yang, Qingqing Liu, Dawei Wang, Zhen Zhao, Zhaohai Su, Daping Fan, Qing Liu
BACKGROUND: Sparstolonin B (SsnB) is characterized as a new toll-like receptor (TLR)-2/4 antagonist. However, the effects of SsnB on different inflammatory diseases have not been systemically reviewed. METHODS: We investigated the effects of SsnB on inflammatory diseases with data mining and network analysis of literature, including frequency description, cluster analysis, association rule mining, functional enrichment, and protein-protein interaction (PPI) mining...
January 25, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38270690/comparison-between-drug-coated-balloon-and-stents-in-large-de-novo-coronary-artery-disease-a-systematic-review-and-meta-analysis-of-rct-data
#32
REVIEW
Zhiqiang Ma, Kanling Liu, Yanhui Hu, Xiwen Hu, Binyu Wang, Zhengyi Li
PURPOSE: Although a number of studies involving small-vessel de novo coronary disease showed clinical benefits of drug-coated balloons (DCB), the role of DCB in large vessel lesions is still unclear. METHODS: We searched main electronic databases for randomized controlled trials (RCTs) comparing DCB with stents for large vessel de novo coronary artery disease. The primary endpoint was major cardiovascular adverse events (MACE), composite cardiovascular death (CD), myocardial infarction (MI), or target lesion revascularization (TLR)...
January 25, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38244149/numbers-needed-to-treat-for-preventing-adverse-cardiovascular-outcomes-for-sodium-glucose-cotransporter-2-inhibitors-vs-dipeptidyl-peptidase-4-inhibitors-the-hong-kong-diabetes-study
#33
LETTER
Gary Tse, Sharen Lee, Tong Liu, Jiandong Zhou
No abstract text is available yet for this article.
January 20, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38236378/metabolism-serves-as-a-bridge-between-cardiomyocytes-and-immune-cells-in-cardiovascular-diseases
#34
REVIEW
Lixiao Hang, Ying Zhang, Zheng Zhang, Haiqiang Jiang, Lin Xia
Metabolic disorders of cardiomyocytes play an important role in the progression of various cardiovascular diseases. Metabolic reprogramming can provide ATP to cardiomyocytes and protect them during diseases, but this transformation also leads to adverse consequences such as oxidative stress, mitochondrial dysfunction, and eventually aggravates myocardial injury. Moreover, abnormal accumulation of metabolites induced by metabolic reprogramming of cardiomyocytes alters the cardiac microenvironment and affects the metabolism of immune cells...
January 18, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38224416/evaluation-of-midodrine-utilization-in-patients-with-cancer-and-heart-failure
#35
JOURNAL ARTICLE
Jorge A Irizarry-Caro, Juhee Song, Chase Miller, Shyam Desai, James Going, Jose Fossas-Espinosa, Mariya M Fatakdawala, Abdelrahman Ali, Cezar Iliescu, Nicolas Palaskas, Anita Deswal, Efstratios Koutroumpakis
PURPOSE: The purpose of this study was to evaluate safety and cardiovascular outcomes as well as overall survival of cancer patients with concomitant heart failure (HF) treated with midodrine for hypotension. METHODS: Adult patients diagnosed with cancer and HF who were treated with midodrine at a tertiary cancer center from 03/2013 to 08/2021 were identified. Demographic and clinical parameters were collected retrospectively. RESULTS: A total of 85 patients were included with a median age of 68 years (IQR: 60, 74; 33% female and 85% White)...
January 15, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38224415/the-impact-of-cyp2c19-genotype-on-the-platelet-reactivity-index-pri-among-chronic-coronary-syndromes-ccs-patients-undergoing-percutaneous-coronary-intervention-pci-affectability-of-rapid-genetic-testing
#36
JOURNAL ARTICLE
Mohammed Ahmed Akkaif, Nur Aizati Athirah Daud, Dzul Azri Mohamed Noor, Abubakar Sha'aban, Muhamad Ali Sk Abdul Kader, Baharudin Ibrahim
BACKGROUND: In the Asian population, the presence of the CYP2C19 loss-of-function (LOF) allele is a known genetic variation. This allele is associated with a reduced capacity to metabolize clopidogrel into its active forms through the CYP2C19 enzyme, resulting in diminished platelet inhibition and an elevated risk of recurrent cardiovascular events. Regulatory authorities have recommended an alternative P2Y12 inhibitor, ticagrelor, for individuals carrying the LOF allele. Consequently, this study seeks to assess the impact of the CYP2C19 genotype on the Platelet reactivity index (PRI) using a rapid genetic testing approach in Asian patients with chronic coronary syndromes (CCS) who undergo percutaneous coronary intervention (PCI)...
January 15, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38214869/association-between-the-magnitude-of-glycemic-control-and-body-weight-loss-with-glp-1-receptor-agonists-and-risk-of-atherosclerotic-cardiovascular-disease-a-systematic-review-and-meta-analyses-of-randomized-diabetes-cardiovascular-outcomes-trials
#37
JOURNAL ARTICLE
Daniel A Gomes, João Presume, Pedro de Araújo Gonçalves, Manuel Sousa Almeida, Miguel Mendes, Jorge Ferreira
PURPOSE: Reduction of major atherosclerotic cardiovascular events (MACE) has not been consistent among different glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to assess the association between the magnitude of glycemic control, body weight loss, and reductions in systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) achieved through GLP-1 RA therapy and MACE. METHODS: Electronic databases (MEDLINE, CENTRAL, SCOPUS) were searched through March 2023...
January 12, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38165553/comparative-effectiveness-and-safety-of-direct-oral-anticoagulants-in-low-body-weight-patients-with-atrial-fibrillation-a-systematic-review-and-meta-analysis
#38
REVIEW
Mohamed Nabil Elshafei, Muhammad Salem, Ahmed El-Bardissy, Mohamed S Abdelmoneim, Ahmed Khalil, Sherine Elhadad, Mutasem Al Mistarihi, Mohammed Danjuma
INTRODUCTION: Direct oral anticoagulant (DOAC) agents are established as the anticoagulation strategy of choice for a variety of clinical risks. Despite this, uncertainty still exists with regard to their efficacy and safety for the prevention of stroke and systemic embolism in some patient populations; most notably those with low body weight (LBW) (<60 kg or body mass index [BMI] <18 kg/m2 ). Currently, there is a paucity of trial and non-trial data to support a prescriptive recommendation for their use in these patient cohorts...
January 2, 2024: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38141139/mots-c-peptide-attenuated-diabetic-cardiomyopathy-in-stz-induced-type-1-diabetic-mouse-model
#39
JOURNAL ARTICLE
Nan Wu, Caijie Shen, Jian Wang, Xiaomin Chen, Peng Zhong
BACKGROUND: Diabetic cardiomyopathy (DCM) pathogenesis is a common complication of diabetes, but effective treatments remain limited. Mitochondrial-derived peptide MOTS-c has shown therapeutic promise in animal models of various heart diseases, but its efficacy in DCM is unknown. This study investigates the effects of MOTS-c treatment in a mouse model of type 1 diabetes-induced DCM. METHODS: Type 1 diabetes (T1DM) was induced in mice by streptozotocin (STZ) injection...
December 23, 2023: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38117423/the-infarct-limiting-effect-of-remote-ischemic-conditioning-in-rats-is-not-affected-by-aspirin
#40
JOURNAL ARTICLE
M V Basalay, James M Downey, S M Davidson, D M Yellon
PURPOSE: Remote ischemic conditioning (RIC) has been shown to be a powerful cardioprotective therapy in animal models. However, a protective effect in patients presenting with acute myocardial infarction has failed to be confirmed. A recent pre-clinical study reported that aspirin which is routinely given to patients undergoing reperfusion therapy blocked the infarct-limiting effect of ischemic postconditioning. The present study was designed to test whether aspirin could also be blocking the infarct-limiting effect of RIC...
December 20, 2023: Cardiovascular Drugs and Therapy
journal
journal
29693
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.